Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L01 ANTINEOPLASTIC AGENTS
L01X OTHER ANTINEOPLASTIC AGENTS
L01XG Proteasome inhibitors
L01XG01 Bortezomib
D03150 Bortezomib (JAN/USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Antineoplastics
Molecular Target Inhibitors
Bortezomib
D03150 Bortezomib (JAN/USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
429 Miscellaneous
4291 Other Antitumors
D03150 Bortezomib (JAN/USAN/INN)
Drug groups [BR:br08330]
Antineoplastic
DG03134 Proteasome inhibitor
DG03219 Bortezomib
D03150 Bortezomib
Target-based classification of drugs [BR:br08310]
Enzymes
Hydrolases (EC3)
Threonine peptidases
PSMB5
D03150 Bortezomib (JAN/USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D03150
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D03150
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D03150
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D03150
Drug groups [BR:br08330]
Antineoplastic
DG03134 Proteasome inhibitor
DG03219 Bortezomib